OPK
OPKO HEALTH, INC.
$1.42
-2.07%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusBuy (64%)
Inst. Holders50 funds
Inst. Value$175.1M
Inst. Activity11 buys / 4 sells
Insider Activity1B / 0S
Insider Net $$11.3K
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases2
Recent Activity
May 15, 2026
SEC
OPKO Health filed a DEFA14A supplement clarifying that its 2016 Equity Incentive Plan expired in February 2026, renderin
DEFA14A — Impact 4/10
Apr 21, 2026
SEC
OPKO Health announced it will report Q1 2026 earnings on April 28, 2026, after market close, followed by a conference ca
PRESS-RELEASE — Impact 3/10
Mar 20, 2026
Insider
PAGANELLI JOHN A bought 10,000 shares
Director @ $1.14 ($11.3K)
Mar 18, 2026
Insider
UPPALURI SUBBARAO V was granted 50,000 shares
Director
Inst.
MORGAN STANLEY — ADD
1,196,087 shares ($1.4M)
Inst.
BANK OF AMERICA CORP — ADD
1,141,849 shares ($1.3M)
May 22, 2026
short_volume
Short Volume: OPK — 56.0% short (0.7M / 1.3M)
Short: 708,597 | Exempt: 2,578 | TRF Vol: 1,264,589 | Short Ratio: 56.0% | Off-exchange volume (dark
Apr 30, 2026
Press
OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in excha
Impact 4/10
Price Targets
$3.76
+164.8% upside
Strong Buy
Current $1.42
Low $1.30
Median $3.00
High $8.50
5 analysts
$1.30
$8.50
Analyst Ratings
2Strong Buy
5Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | Barrington Research | DOWNGRADE | Outperform → Market Perform |
| Mar 2, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 | $-0.11 — $-0.11 | -34% YoY | 1 |
| Next Q | $-0.11 ▼ -37.5% | $-0.11 — $-0.11 | 1 | |
| Current FY | $-0.38 ▼ -11.8% | $-0.38 — $-0.38 | 1 | |
| Next FY | $-0.32 ▲ +3.0% | $-0.32 — $-0.32 | 16% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
4/10
OPKO Health filed a DEFA14A supplement clarifying that its 2016 Equity Incentive Plan expired in February 2026, renderin
May 15, 2026
NEUTRAL
Press
4/10
OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in excha
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
3/10
OPKO Health announced it will report Q1 2026 earnings on April 28, 2026, after market close, followed by a conference ca
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Rubric Capital Management LP | $54.5M | — |
| BlackRock, Inc. | $41.3M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $16.8M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.5M | — |
| STATE STREET CORP | $10.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 20, 2026 | PAGANELLI JOHN | BUY | $11.3K |
| Mar 18, 2026 | UPPALURI SUBBARAO | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $175.1M total value (153,548,196 shares) as of 2026-Q1. Top holders: Rubric, BlackRock,, VANGUARD. Net buying activity: 11 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 47,791,243 | $54.5M | 31.1% | — |
| 2 | BlackRock, Inc. | 36,232,223 | $41.3M | 23.6% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 14,769,719 | $16.8M | 9.6% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 14,499,164 | $16.5M | 9.4% | — |
| 5 | STATE STREET CORP | 9,501,377 | $10.8M | 6.2% | — |
| 6 | GOLDMAN SACHS GROUP INC | 7,675,026 | $8.7M | 5.0% | — |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3,574,039 | $4.1M | 2.3% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 2,742,017 | $3.1M | 1.8% | — |
| 9 | CITADEL ADVISORS LLC | 2,079,547 | $2.4M | 1.4% | ADD +28.7% |
| 10 | DIMENSIONAL FUND ADVISORS LP | 1,560,000 | $1.8M | 1.0% | — |
| 11 | MORGAN STANLEY | 1,196,087 | $1.4M | 0.8% | ADD +30.4% |
| 12 | VOYA INVESTMENT MANAGEMENT LLC | 1,160,927 | $1.3M | 0.8% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 1,141,849 | $1.3M | 0.7% | ADD +84.7% |
| 14 | Nuveen, LLC | 846,993 | $965.6K | 0.6% | TRIM -25.3% |
| 15 | Invesco Ltd. | 793,169 | $904.2K | 0.5% | TRIM -25.8% |
| 16 | Assenagon Asset Management S.A. | 652,066 | $740.3K | 0.4% | TRIM -26.2% |
| 17 | Connor, Clark & Lunn Investment Management Ltd. | 522,906 | $596.1K | 0.3% | — |
| 18 | FIRST TRUST ADVISORS LP | 500,273 | $570.3K | 0.3% | — |
| 19 | RHUMBLINE ADVISERS | 497,240 | $566.8K | 0.3% | — |
| 20 | ALLIANCEBERNSTEIN L.P. | 423,190 | $533.2K | 0.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 917,353 | 1,196,087 | +30.4% | $1.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 618,259 | 1,141,849 | +84.7% | $1.3M | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 641,456 | 430,906 | -32.8% | $491.2K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 229,590 | 122,128 | -46.8% | $139.2K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 26,366 | 65,556 | +148.6% | $74.7K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 85,348 | 45,919 | -46.2% | $52.3K | 2026-Q1 |
| FMR LLC | DOUBLED | 14,087 | 41,343 | +193.5% | $47.1K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 26,437 | 34,714 | +31.3% | $39.6K | 2026-Q1 |
| Swiss Life Asset Management Ltd | ADD | 19,164 | 28,488 | +48.7% | $32.5K | 2026-Q1 |
| Cerity Partners LLC | ADD | 17,382 | 23,471 | +35.0% | $26.8K | 2026-Q1 |
| Allworth Financial LP | ADD | 8,151 | 11,661 | +43.1% | $13.3K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 6,045 | 9,221 | +52.5% | $10.5K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 1,312 | 3,388 | +158.2% | $3.9K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 401 | 1,053 | +162.6% | $1.2K | 2026-Q1 |
| HRT FINANCIAL LP | NEAR_EXIT | 675,483 | 90,759 | -86.6% | $103.00 | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,255,647 | 734,747 | -41.5% | $925.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,313,882 | 618,259 | -52.9% | $779.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 342,486 | 468,518 | +36.8% | $590.3K | 2025-Q4 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | TRIM | 81,525 | 52,815 | -35.2% | $66.5K | 2025-Q4 |
| Verition Fund Management LLC | TRIM | 79,534 | 50,650 | -36.3% | $63.8K | 2025-Q4 |
| Mariner, LLC | TRIM | 69,006 | 42,225 | -38.8% | $53.3K | 2025-Q4 |
| CAPTRUST FINANCIAL ADVISORS | TRIM | 68,026 | 40,120 | -41.0% | $50.6K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 57,050 | 37,000 | -35.1% | $46.6K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 39,097 | 26,437 | -32.4% | $33.3K | 2025-Q4 |
| PRUDENTIAL FINANCIAL INC | TRIM | 54,772 | 26,366 | -51.9% | $33.2K | 2025-Q4 |
2 unique insiders with 2 transactions. Net insider value: $11.3K ($11.3K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 20, 2026 | PAGANELLI JOHN A | Director | BUY | 10,000 | $1.14 | $11.3K |
| Mar 18, 2026 | UPPALURI SUBBARAO V | Director | AWARD | 50,000 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.5/10.
Current analyst consensus: Buy (64% buy). Based on 11 analysts: 2 strong buy, 5 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.76 mean target
+164.8% upside
Strong Buy (3.00)
$1.30 Low
$8.50 High
| Metric | Value |
|---|---|
| Current Price | $1.42 |
| Target Low | $1.30 |
| Target Mean | $3.76 |
| Target Median | $3.00 |
| Target High | $8.50 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.11 | $-0.11 | -34.0% | — | — | $0.1B | -16.4% | 1 |
| Next Q 2026-09-30 |
$-0.11 | $-0.11 | $-0.11 | — | -37.5% | — | $0.1B | -10.6% | 1 |
| Current FY 2026-12-31 |
$-0.38 | $-0.38 | $-0.38 | — | -11.8% | 0↑ 1↓ | $0.5B | -11.4% | 1 |
| Next FY 2027-12-31 |
$-0.32 | $-0.32 | $-0.32 | 15.8% | +3.0% | 1↑ 0↓ | $0.6B | 5.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.110 | |
| 7d ago | $0.000 | -0.110 |
| 30d ago | $0.000 | -0.110 |
| 60d ago | $-0.080 | -0.030 |
| 90d ago | $-0.080 | -0.030 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | Barrington Research | DOWNGRADE | Outperform | Market Perform |
| Mar 2, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 4 | 0 | 0 | 64% | |
| May 1, 2026 | 2 | 5 | 4 | 0 | 0 | 64% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jan 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
OPK
▲ 1
💬 0
⚡ 0.5
May 22, 2026
short_volume
Short Volume: OPK — 56.0% short (0.7M / 1.3M)
Short: 708,597 | Exempt: 2,578 | TRF Vol: 1,264,589 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: OPK — 56.5% short (0.6M / 1.0M)
Short: 583,139 | Exempt: 4,398 | TRF Vol: 1,031,736 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: OPK — 65.2% short (0.7M / 1.1M)
Short: 711,803 | Exempt: 0 | TRF Vol: 1,092,559 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: OPK — 55.3% short (0.5M / 1.0M)
Short: 545,225 | Exempt: 5,474 | TRF Vol: 985,249 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: OPK — 55.9% short (0.4M / 0.8M)
Short: 422,531 | Exempt: 1,599 | TRF Vol: 756,233 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: OPK — 66.5% short (0.5M / 0.8M)
Short: 517,459 | Exempt: 0 | TRF Vol: 778,169 | Short Ratio: 66.5% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: OPK — 67.7% short (0.6M / 0.9M)
Short: 599,049 | Exempt: 2,301 | TRF Vol: 884,553 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
May 3, 2026
Clinical Trial
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Phase Phase 2 — TERMINATED
Apr 30, 2026
contract
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
Grants OPKO a 15% equity interest in Nicoya <pre>Grants OPKO a 15% equity interest in Nicoya</pre>
Apr 30, 2026
short_volume
Short Volume: OPK — 73.1% short (0.9M / 1.2M)
Short: 884,845 | Exempt: 30,445 | TRF Vol: 1,210,872 | Short Ratio: 73.1% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: OPK — 57.7% short (3.7M / 6.4M)
Short: 3,667,288 | Exempt: 382,221 | TRF Vol: 6,353,728 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
earnings
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today <pre>Conference call begins at 4:30 p.m. Eastern time today</pre>
Apr 28, 2026
earnings_calendar
OPK Q1 2026 Earnings Scheduled — 2026-04-28
Apr 22, 2026
fda
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
<p align="center"><em>Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymph
Apr 21, 2026
earnings
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
<p align="justify">MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK)</strong> plans to report operating and financia
Mar 25, 2026
short_volume
Short Volume: OPK — 58.0% short (1.1M / 1.9M)
Short: 1,084,135 | Exempt: 300 | TRF Vol: 1,869,198 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)